Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 25.60
- Piotroski Score 0.00
- Grade Buy
- Symbol (GNTA)
- Company Genenta Science S.p.A.
- Price $4.69
- Changes Percentage (-2.21%)
- Change -$0.11
- Day Low $4.66
- Day High $4.99
- Year High $7.28
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.70
- Trailing P/E Ratio -4.71
- Forward P/E Ratio -4.71
- P/E Growth -4.71
- Net Income $-11,645,455
Income Statement
Quarterly
Annual
Latest News of GNTA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Genenta Science S.p.A. (GNTA): Early Investment Opportunity in Innovative Biotech
Italy's economy faces challenges like slower growth and high public debt. Genenta Science S.p.A. (NASDAQ:GNTA) is highlighted as a top Italian stock pick due to its innovative biotechnology approach. ...
By Yahoo! Finance | 1 month ago
